Washington, D.C. (October 31, 2021) – The Association for Accessible Medicines’ Biosimilars Council, in accordance with the International Generic and Biosimilar Medicines Association (IGBA), invites all biosimilars advocates and stakeholders to take part in the second annual Global Biosimilars Week on November 1-5. This social media awareness campaign will gather biosimilar resources, ideas and stories from around the world under the hashtag #GlobalBiosimilarsWeek.
“The growing use of biosimilar medicines is revolutionizing global health, as they help more patients access treatments for serious chronic illnesses at a fraction of the cost of brand-name biologics. However, many people still lack awareness of biosimilars and the incredible benefits they provide. Global Biosimilars Week is meant to bridge that awareness gap,” said Biosimilars Council Executive Director Christine Simmon. “The Biosimilars Council has been proud to organize this event and engage with our counterparts around the world. By sharing our unique resources and stories, we will present a unified voice for biosimilars that will extend well beyond this week and ultimately achieve our shared goal of advancing biosimilar access for all.”
“The COVID-19 global health crisis has led governments and the entire health care community to rethink and rebuild health care systems. This includes focusing on their ability to efficiently deliver access to biologic therapies and to effectively address Non-Communicable Diseases (NCD),” explained Sudarshan Jain, Chair of the IGBA. “Now is a time to reconcile the unique opportunity provided by the availability of biosimilar medicines and the rising challenges for many patients around the world to access quality-assured transformative therapies. We need to redouble the efforts to effectively tackle NCDs and biosimilar medicines are part of the solution.”
“With 15 years of positive biosimilar medicines contribution to patient health and health care system sustainability, the challenges and remedies to efficient use of biosimilar medicines are well known. Our new white paper aims to facilitate experience sharing for communities wanting to Advance Access in their country or region and more importantly to implement effective and tailored strategies in tackling Non-Communicable Diseases locally,” said Julie Maréchal-Jamil, Co-Chair of the IGBA Biosimilars Committee.
Additionally, on November 2, IGBA will host an online webinar “Unlocking the Global Biosimilar Opportunity in Tackling Non-Communicable Diseases” to provide valuable information and expert insights.
MEDIA CONTACT:
Rachel Schwartz
202.249.7147
